People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Coya Therapeutics, Inc. | — | Biotechnology | Series B | $56.9M | $62.3M | 2022 |
| Invenra Inc. | — | Pharmaceuticals | Series A | $21.3M | $220.8M | 2013 |
| Victory Pharma Inc | — | Pharmaceuticals | Series A | $10.0M | $309.7M | 2009 |
| BTB Therapeutics, Inc. | — | Pharmaceuticals | Seed | $6.7M | $7.9M | 2025 |
| Go4Ellis, Inc. | — | Other Technology | Seed | $1.5M | $29.3M | 2021 |
David Snyder at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Snyder on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Parker | 1 | 11 |
| Dov Goldstein | 1 | 6 |
| Paul Weiss | 1 | 5 |
| Dieter Weinand | 1 | 4 |
| Scott Barry | 1 | 4 |
| Shawn M Titcomb | 1 | 3 |
| Herbert Hooper | 1 | 3 |
| Thomas Wiggans | 1 | 3 |
| Stan Rose | 1 | 3 |
| Hideki Garren | 1 | 2 |
| Emile Nuwaysir | 1 | 2 |
| Richard Lesniewski | 1 | 2 |
| Andrew Hayes | 1 | 2 |
| Andy Kaplan | 1 | 2 |
| Matthew Heck | 1 | 2 |
| James Newman | 1 | 2 |
| Anabella Villalobos | 1 | 1 |
| Ann Lee | 1 | 1 |
| Fred Grossman | 1 | 1 |
| Wilbur Ross | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.